Navigation Links
Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
Date:6/13/2011

d each year and that there were nearly 15,000 deaths from bladder cancer in the United States last year. Bladder cancer is the costliest of all cancers from diagnosis to death. Because bladder cancer has a recurrence rate of 50-80 percent, patients requires life-long monitoring and treatment. Nearly $3 billion is spent in the U.S. alone each year on treatment of bladder cancer.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
2. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
7. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
8. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
9. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
10. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... commercialization of its non-invasive Monarch ™ eTNS™ ... disorders, today announced that enrollment has begun in a ... (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut ... at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Turn the Tide on Antibiotic-Resistant InfectionsPRINCETON, N.J., March ... and the Plexus Institute (Plexus) today announce results ... Staphylococcus aureus (MRSA) prevention program that employed ... and behavioral change, to trigger significant reductions in ...
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
Cached Medicine Technology:CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 2CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 3CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5
(Date:7/22/2014)... Kansas City, MO (PRWEB) July 22, 2014 ... cheap Sporting Kansas City vs. Manchester City tickets at ... match will take place on Wednesday, July 23rd. Tickets ... up to game time. Ticket Down can be reached ... City vs. Manchester City are authentic and covered by Ticket ...
(Date:7/22/2014)... 23, 2014 Provectus has ... From now on, in addition to working with the ... for Google Glass as well as the creation of ... A dynamic lifestyle requires special gadgets for work, leisure ... found application in healthcare, logistics, travelling, sports, education, science ...
(Date:7/22/2014)... NC (PRWEB) July 22, 2014 Obtaining ... faster for military veterans who have hands-on medical experience. ... Carolina at Greensboro today announced the launch of an ... military experience. , The new program, the UNCG Veterans ... cohort of approximately 24 veterans. With some prior college ...
(Date:7/22/2014)... The 2014 Warrior-Family Symposium (WFS) ... Building and International Trade Center in Washington, D.C. ... Civilian Communities,” will be held from 8:30 a.m. ... and cohosted by the Military Officers Association of ... (NDIA). USAA is the Executive Sponsor of the ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 ... be more likely to have children with asthma than normal-weight ... with children born from mothers of normal weight, those whose ... 20 to 30 percent higher odds of asthma," said lead ... Children,s Hospital of Pittsburgh. Forno,s team also found that ...
Breaking Medicine News(10 mins):Health News:Sporting Kansas City vs. Manchester City Tickets: Ticket Down Has Slashed Ticket Prices for Manchester City vs. Sporting Kansas City on July 23rd 2Health News:Provectus Announces Development for Google Glass and Wearables 2Health News:UNCG School of Nursing Fast-Tracks Medically Trained Veterans 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3
... , , BETHESDA, Md., Nov. 16 ... appointment of Michele Perry as chief operating officer. Ms. Perry, ... the company to a new level of growth and deliver ... Interactive Patient Care solution. Among her priorities, Ms. Perry ...
... Experts unsure if growth stems from more awareness or actual ... Pediatric food allergies, which can sometimes be life-threatening, are increasing ... shows. , But the study authors aren,t sure if the ... actual prevalence or if better awareness has led more people ...
... , SINGAPORE, Nov. 16 ... of Malaysia grew steadily in the first half of 2009 ... and,aggressive promotions from major Contact Lens manufacturers. Positive sales,data showing ... cemented,the view of an economic recovery that is being led ...
... ... Interactive Regulatory Compliance Training Provides Critical Strategies for Successful Interactions Between Life Science ... ... Stimaré , a specialized sales enablement and IT consulting company, today announced ...
... ... Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive Apparel (RDAA), a ... launch of “Cool Clothes for Toes,” the first creatively styled sock line for children and ...
... NANJING, China, Nov. 16 /PRNewswire-Asia/ -- Simcere ... leading pharmaceutical company,specializing in the development, manufacturing, and marketing of branded,generic ... quarter ended September 30, 2009. , , Highlights, ... for the third, quarter of ...
Cached Medicine News:Health News:GetWellNetwork Taps High-Tech Veteran Michele Perry as Chief Operating Officer 2Health News:Child Food Allergies on the Rise in U.S. 2Health News:Child Food Allergies on the Rise in U.S. 3Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: